How to Value a Home Health Agency in 2026

Having spent the better part of my career in healthcare M&A, I can tell you that home health is one of the most complex verticals to value correctly. Unlike a dental practice or a SaaS company where you can look at a few key metrics and get directionally accurate, home health valuation requires understanding Medicare reimbursement mechanics, state licensing laws, quality ratings, and payer mix at a level that most generalist advisors simply don't have.

Our database tracks 226 home health transactions with a median EV/EBITDA of 8.3x and a median EV/Revenue of 0.91x. But those medians mask enormous variation. I've seen Medicare-certified agencies in CON (Certificate of Need) states sell for 12-15x EBITDA, while non-medical home care agencies in open-license states struggle to get 3x. Understanding where your agency falls — and why — is what this guide is about.

Skilled Home Health vs. Non-Medical Home Care: Two Different Businesses

The first distinction that drives everything in home health valuation is whether your agency provides skilled services (nursing, physical therapy, occupational therapy, speech therapy) or non-medical personal care (bathing, dressing, meal prep, companionship). These are fundamentally different businesses with different economics, different regulatory profiles, and different valuations.

Medicare-Certified Home Health Agencies

Skilled home health agencies certified by Medicare operate under the PDGM (Patient-Driven Groupings Model) reimbursement system. Medicare is typically the dominant payer, representing 60-80% of revenue for most agencies. These agencies employ or contract with RNs, PTs, OTs, and other licensed clinicians.

Medicare-certified agencies command premium valuations for several reasons: Medicare reimbursement provides predictable revenue, the certification process creates barriers to entry, and the referral relationships with hospitals and physicians are durable assets. I typically see Medicare-certified agencies selling for 7-12x EBITDA, with the wide range driven by star ratings, CON protections, and census levels.

Non-Medical Home Care Agencies

Non-medical agencies provide personal care aides and companions, funded primarily through Medicaid waiver programs, long-term care insurance, and private pay. These agencies have lower barriers to entry (most states require only a basic license), lower reimbursement rates, and higher caregiver turnover.

Valuations for non-medical home care are considerably lower: 3-6x EBITDA is typical. The discount reflects easier market entry, lower margins, and the labor-intensive nature of the business. However, non-medical agencies with strong Medicaid managed care contracts or significant private pay revenue can push toward the higher end of this range.

PDGM and Medicare Reimbursement

If you operate a Medicare-certified agency, PDGM is the system that determines your revenue per patient episode. Implemented in 2020, PDGM replaced the old PPS (Prospective Payment System) and fundamentally changed how home health agencies are reimbursed.

Under PDGM, each 30-day period of care is classified into one of 432 payment categories based on the patient's admission source (community vs. institutional), clinical grouping, functional impairment level, and comorbidity adjustment. The average Medicare payment per 30-day period runs roughly $2,000-$2,800 depending on your patient mix.

What buyers scrutinize in PDGM data:

• Case mix weight: Higher case mix weights indicate sicker, more complex patients who generate higher reimbursement. An agency with average case mix weight of 1.15 is worth more per episode than one at 0.95.
• LUPA (Low Utilization Payment Adjustment) rate: Episodes with fewer than the threshold number of visits get paid a reduced per-visit rate instead of the full 30-day payment. High LUPA rates (above 8-10%) signal operational inefficiency and reduce per-patient revenue. Buyers flag this immediately.
• Institutional vs. community referrals: Institutional referrals (hospital discharges) receive higher payment adjustments under PDGM. Agencies with strong hospital discharge relationships generate more revenue per patient.
• Early vs. late episodes: PDGM pays more for early episodes (first 30 days) than late episodes. Agencies that efficiently manage patient care within 1-2 episodes rather than extending to 3-4 are more profitable.

Star Ratings: The Quality Premium

CMS publishes star ratings (1-5 stars) for every Medicare-certified home health agency based on quality of care measures and patient satisfaction. These ratings directly impact valuation in two ways.

First, star ratings affect patient referrals. Hospital discharge planners, physicians, and care coordinators use star ratings to select home health partners. A 4.5-star agency gets referrals that a 2.5-star agency doesn't. More referrals mean higher census, and census drives revenue.

Second, CMS has implemented the Home Health Value-Based Purchasing (HHVBP) model nationally, which adjusts Medicare payments based on quality performance. High-performing agencies receive payment bonuses of up to 5%, while low performers face penalties. Over a five-year horizon, the cumulative impact of HHVBP bonuses versus penalties can represent a 20-25% swing in Medicare revenue.

In my experience, the star rating premium in M&A is substantial. Agencies with 4+ stars typically sell for 1.5-2x higher EBITDA multiples than comparable agencies with 3 stars or below. Buyers are paying for the referral pipeline and the HHVBP payment bonuses.

Certificate of Need: The Regulatory Moat

Fifteen states currently require a Certificate of Need (CON) to operate a Medicare-certified home health agency. In CON states, you can't simply open a new agency — you must obtain regulatory approval, which often involves proving community need and can take years or may not be granted at all.

CON creates an economic moat that dramatically impacts valuation. An agency operating in a CON state faces limited competition and can't be easily replicated. Buyers are effectively paying for the license as much as the business operations.

I've seen agencies in states like Georgia, North Carolina, and Tennessee — all CON states — sell for 30-50% premiums over comparable agencies in non-CON states like Texas or Florida. In some cases, the CON itself represents the majority of the enterprise value, particularly for agencies with small censuses in underserved markets where the growth opportunity (protected by the CON) is the primary asset.

The flip side: agencies in non-CON states face constant competitive pressure. New entrants can open down the street and compete for the same referral sources. Valuations in open-license states are lower but more dependent on operational quality and relationships rather than regulatory protection.

The Aging Population Tailwind

Home health has the most favorable demographic tailwind of any healthcare sectorI cover. The 65+ population is growing at roughly 3% annually, the 85+ population (the heaviest users of home health) is the fastest-growing age cohort in the country, and there's a clear policy and consumer preference for home-based care over institutional settings.

CMS data shows Medicare home health spending has grown at approximately 4-5% annually, and that trajectory is expected to accelerate. Buyers — particularly PE firms building home health platforms — are underwriting 5-7 year growth assumptions that are more conservative than the actual demographic trend, which means they can afford to pay premium multiples today.

This secular growth story is why home health has attracted enormous PE capital. Amedisys, LHC Group, BrightSpring, and Enhabit are all platform-scale home health companies that continue to acquire. The consolidation trend shows no sign of slowing.

What Drives Home Health Valuations Up

• CON state location: The single biggest premium driver. Regulatory protection is worth paying for.
• 4+ star rating: Demonstrates quality and drives referrals.
• Low LUPA rate (under 7%): Indicates efficient clinical operations and strong revenue per episode.
• Diversified referral sources: Relationships with multiple hospitals and physician groups, not dependent on one referral source.
• Growing census: Monthly average daily census trending upward over 2-3 years shows market share gains.
• Mixed-payer capability: Agencies that accept Medicare, Medicaid, Medicare Advantage, and commercial insurance have a broader patient base and less concentration risk.
• Employed clinical staff: Agencies using employed nurses and therapists (versus independent contractors) have better quality control, lower regulatory risk, and more predictable costs.

What Kills Home Health Valuations

• Survey deficiencies: Recent state survey deficiencies, especially condition-level deficiencies, are deal-killers. Buyers will walk away or demand significant price reductions for agencies with unresolved compliance issues.
• High LUPA rates: Above 12-15% signals clinical and operational problems that reduce per-patient profitability.
• Declining census: Falling patient volumes indicate referral relationship deterioration or competitive pressure.
• Caregiver turnover above 70%: The industry average is already high, but agencies that can't retain clinical staff face a vicious cycle: short-staffing leads to quality problems, which lead to referral losses, which lead to census decline.
• Single-payer dependency: Agencies that are 90%+ Medicare face concentration risk from rate changes and policy shifts. Medicare Advantage penetration is growing, and agencies that can't contract with MA plans are losing market share.
• Compliance history: Any history of False Claims Act settlements, OIG investigations, or Medicare fraud allegations creates severe buyer concerns — even if the issues were resolved years ago.

Preparing Your Home Health Agency for Sale

Maximize your star rating. This is a 12-18 month project, but the ROI in valuation terms is enormous. Focus on the quality measures CMS weights most heavily: timely initiation of care, improvement in ambulation, and acute care hospitalization rates. A single-star improvement can add 1-2x to your EBITDA multiple.

Reduce your LUPA rate. Audit your clinical operations to ensure patients receive the threshold number of visits in each 30-day episode. Often, high LUPA rates stem from scheduling inefficiency rather than clinical judgment.

Diversify your payer mix.If you're 85%+ Medicare, actively pursue Medicaid waiver contracts and Medicare Advantage plan agreements. Even moving to 70% Medicare / 15% MA / 15% Medicaid signals to buyers that your revenue isn't single-source dependent.

Build referral relationships broadly.If 50% of your admissions come from one hospital, that's a concentration risk. Develop relationships with physician practices, assisted living facilities, and community organizations to diversify your referral pipeline.

Ensure compliance is spotless. Conduct a mock survey with a compliance consultant. Fix every deficiency before going to market. Buyers will request your last 3-5 years of state surveys, and any patterns of non-compliance will suppress your valuation or kill the deal entirely.

The Bottom Line

Home health is a growing market with strong buyer demand and favorable demographics. The agencies that command premium multiples — 8x, 10x, or higher — are those with high star ratings, CON protections, diversified referrals, and clean compliance records. The agencies that struggle to sell are those with survey deficiencies, declining census, and dependency on a single payer or referral source. If you're planning an exit, the value creation roadmap is clear: invest in quality, diversify your revenue sources, and get your compliance house in order. The market will reward you for it.